Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

M. Chan, L. Haydu, A. M. Menzies, M. Azer, O. Klein, M. Lyle, A. Clements, A. Guminski, R. Kefford, G. Long

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)42-42
Number of pages1
JournalAsia-Pacific Journal of Clinical Oncology
Issue numberSupplement 2
Publication statusPublished - Jul 2013
Externally publishedYes

Cite this